Thalomid R Phase I II Clinical
Selected Abstract
Thalomid(R) Phase I/II Clinical Data Presented as Combination Therapy For Treating Prostate Cancer; 76 of evaluable patients demonstrated prostate-specific antigen response in second line therapy.
Celgene Corporation announced today the results of data presented at the European Cancer Conference (ECCO) in Copenhagen, Denmark which used THALOMID(R) in combination with chemotherapy androgen-independent prostate carcinoma (AIPCa). The Phase I/II study results demonstrated that 18 of 33 (55) ... September 25, 2003; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Thalomid(R) Phase I/II Clinical Data Presented as Combination Therapy For Treating Prostate Cancer; 76 of evaluable patients demonstrated prostate-specific antigen response in second line therapy.
|
